For payers and insurers Update approved drug lists and budget impact models
T.DiehlT
Daniela Hurtado, an endocrinologist at the Mayo Clinic
Most patients weigh factors like the molecule and brand, what theyre being treated for, their insurance situation, and how their body responds to a particular treatment
It can be hard to tell the difference between GLP-1 side effects and an overdose, as they often look the same
Not well supported: High-quality, reproducible human trials demonstrating meaningful improvement in tendon/ligament healing time, re-injury rates, or function with these specific compoundsespecially as used in the wild (variable dosing, variable sourcing, variable diagnosis)